# US 2021/0332121 A1 · Combination therapy using an il-20 antagonist and an immune checkpoint inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332121 A1
- Document ID: US20210332121A1
- Status: Published application
- Kind: A1
- Application number: 16/855,637
- Filed: 2020-04-22
- Published: 2021-10-28
- Earliest claimed: 2020-04-22
- Assignees: LBL Biotechnology Inc.
- Applicants: LBL Biotechnology Inc.
- Inventors: Ming-Shi CHANG
- Web page: https://patentgrep.com/patent/US20210332121A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions relating to combination therapy using an IL-20 antagonist and an immune checkpoint inhibitor are provided.

## Claims

### Claim 1

A method for treating a cancer or a fibrosis or delaying the onset of a cancer or a fibrosis in a subject, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical combination comprising an IL-20 antagonist and a immune checkpoint inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the the IL-20 antagonist the anti-IL-20 antagonist is an antibody that binds to IL-20

### Claim 3 (depends on 1)

The method of claim 1, wherein the antibody is an antibody that binds human IL-20.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antibody is a full-length antibody or an antigen-binding fragment thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody is a human antibody, a humanized antibody, a chimeric antibody, or a single-chain antibody.

### Claim 6 (depends on 1)

The method of claim 1, wherein the anti-IL-20 antibody binds to the same epitope of human IL-20 as monoclonal antibody mAb7E or competes against mAb7E from binding to human IL-20.

### Claim 7 (depends on 1)

The method of claim 1, wherein the antibody comprises the same heavy chain complementary determining regions (CDRs) as mAb7E and the same light chain CDRs as mAb7E.

### Claim 8 (depends on 1)

The method of claim 1, wherein the antibody is a humanized antibody of mAb7E.

### Claim 9 (depends on 1)

The method of claim 1, wherein the humanized antibody comprises a heavy chain variable region (VH), which comprises the amino acid sequence of SEQ ID NO:8, and a light chain variable region (VL), which comprises the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:13.

### Claim 10 (depends on 1)

The method of claim 1, wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody, anti-PD-1 antibody or an anti-PD-L1 antibody.

### Claim 11 (depends on 1)

The method of claim 1, wherein the immune checkpoint inhibitor is pembrolizumab, pidilizumab, nivolumab, durvalumab, avelumab, atezolizumab, toripalimab, sintilimab, camrelizumab or MIHI.

### Claim 12 (depends on 1)

The method of claim 1, wherein the IL-20 antagonist and the immune checkpoint inhibitor are administered concurrently, separately or sequentially.

### Claim 13 (depends on 1)

The method of claim 1, wherein the cancer is pancreatic cancer, glioblastoma, liver cancer, colorectal carcinoma, glioblastoma, gastric cancer, colorectal cancer, esophageal cancer, lung cancer, renal cell carcinoma, benign prostate hyperplasia, prostate cancer, ovarian cancer, melanoma, breast cancer, chronic lymphocytic leukemia (CLL), Merkel cell carcinoma, Non-Hodgkin lymphoma, acute myeloid leukemia (AML), gallbladder cancer, cholangiocarcinoma, urinary bladder cancer, and uterine cancer.

### Claim 14 (depends on 13)

The method of claim 13, wherein the pancreatic cancer is adenocarcinoma or non-adenocarcinoma.

### Claim 15 (depends on 1)

The method of claim 1, wherein the fibrosis is a pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren disease, nonalcoholic steatohepatitis, liver fibrosis, portal hypertension, systemic sclerosis, renal fibrosis, cardiac fibrosis, and cutaneous fibrosis.
